new
   Side effects of Quizartinib
502
Jul 15, 2025

Quizartinib is a targeted therapy for FLT3 mutation-positive acute myeloid leukemia, which has shown certain efficacy in clinical applications. Its use is also accompanied by a series of side effects. This article will discuss in detail the side effects, mitigation measures and daily precautions of Quizartinib, aiming to provide a reference for patients.

Side effects of Quizartinib

Quizartinib may cause a variety of side effects during treatment, posing a challenge to the patient's health.

QT interval prolongation

Quizartinib may cause QT interval prolongation, which is an abnormal manifestation on the electrocardiogram and may increase the risk of arrhythmia. Patients need to pay close attention to electrocardiogram changes during medication and take corresponding measures if necessary.

Bone marrow suppression

Quizartinib may cause bone marrow suppression, leading to thrombocytopenia, neutropenia, anemia and leukopenia. These side effects may increase the risk of infection and bleeding, and regular blood routine tests are required.

Nausea, vomiting and diarrhea

Gastrointestinal symptoms are one of the common side effects of Quizartinib, including nausea, vomiting and diarrhea. These symptoms may cause patients to lose their appetite and poor nutrient absorption, which in turn affects their overall health.

The side effects of Quizartinib cannot be ignored, but through reasonable monitoring and management, its impact on patients can be alleviated to a certain extent.

Side effect mitigation measures of Quizartinib

A series of mitigation measures can be taken for the side effects of Quizartinib to improve the patient's tolerance and quality of life.

ECG monitoring and electrolyte correction

To prevent arrhythmias caused by QT interval prolongation, patients should undergo regular ECG examinations before and during the use of Quizartinib, and monitor electrolyte levels such as potassium and magnesium, and perform electrolyte correction when necessary.

Blood transfusion and growth factor therapy

For hematopoiesis caused by bone marrow suppression, blood transfusion, growth factor therapy and other measures can be taken according to the specific situation to maintain the number of blood cells within the normal range.

Drug treatment and dietary adjustment

For digestive tract symptoms, antiemetics, antidiarrheal drugs and other drugs can be used for symptomatic treatment, adjust the diet structure, choose light and easily digestible food, and avoid increasing the gastrointestinal burden.

The above mitigation measures can effectively reduce the side effects of Quizartinib and improve the patient's treatment compliance and quality of life.

Daily precautions for Quizartinib

During the use of Quizartinib, patients need to follow certain daily precautions.

Regular monitoring and follow-up

Patients should regularly monitor electrocardiograms, blood routine tests, etc. to promptly detect and deal with side effects. Regular follow-up helps evaluate the treatment effect and adjust the treatment plan.

Avoid drug interactions

Quizartinib may interact with certain drugs, such as strong CYP3A inhibitors and inducers. Patients should consult a doctor before use to avoid using drugs that may cause adverse reactions at the same time.

Lifestyle adjustments

During the use of Quizartinib, patients should pay attention to maintaining good living habits, such as regular work and rest, moderate exercise, and a balanced diet, so as to improve their body's immunity and reduce the discomfort caused by side effects.

Daily precautions for Quizartinib are very important for the smooth progress of treatment. Patients should actively cooperate with the doctor's guidance and follow the relevant precautions to achieve the best treatment effect.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Quizartinib(VANFLYTA)
VANFLYTA is indicated for adult patients with newly diagnosed Acute Myeloid Leukemia (AML) that is FLT3 Internal Tandem Duplication (ITD)-positive, as detected by an FDA-approved...
RELATED ARTICLES
Precautions when taking Quizartinib

Quizartinib (Vanflyta) is indicated for the treatment of newly diagnosed adult patients with acute myeloid...

Tuesday, July 15th, 2025, 14:50
Side effects of Quizartinib

Quizartinib is a targeted therapy for FLT3 mutation-positive acute myeloid leukemia, which has shown certain...

Tuesday, July 15th, 2025, 13:38
How effective is Quizartinib(Vanflyta)?

Quizartinib (Vanflyta) is a targeted therapy for FLT3 mutation-positive acute myeloid leukemia (AML). It has...

Tuesday, July 15th, 2025, 11:53
How to use Quizartinib

Quizartinib is a therapeutic drug for patients with specific acute myeloid leukemia (AML). This article aims to...

Tuesday, July 15th, 2025, 11:44
RELATED MEDICATIONS
Gemtuzumab ozogamicin
Gemtuzumab ozogamicin is a CD33-directed antibody and cytotoxic drug conjugate...
TOP
1
Quizartinib
VANFLYTA is indicated for adult patients with newly diagnosed Acute Myeloid...
TOP
2
Ivosidenib
Adult patients with relapsed or refractory acute myeloid leukemia.
TOP
3
Idelalisib
Indicated for adults with relapsed chronic lymphocytic leukemia (CLL).
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved